banner

China’s biopharmaceutical industry has accelerated its rise into a “new driving force” for steady growth

In the modern biopharmaceutical production workshop of Qilu Pharmaceutical Group Co., Ltd. located in Jinan, Shandong, my country’s first bevacizumab biosimilar drug, Anke, is in full production. This drug, which is mainly used for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer, was launched at the end of last year, breaking the exclusive monopoly of foreign pharmaceutical giants on similar drugs in China for many years, greatly enhancing the clinical use of drugs. Accessibility and affordability.

As one of the leading enterprises in my country’s pharmaceutical industry, Qilu Pharmaceutical achieved sales revenue of 23 billion yuan in 2019 and exports of 615 million US dollars; in the first 11 months of 2020, its product exports increased by 14% year-on-year. At present, Qilu pharmaceutical products have been exported to more than 70 countries and regions around the world.

The biopharmaceutical industry is one of the most innovative and far-reaching strategic emerging industries in the 21st century. Although my country started late in this field, it has developed rapidly. Especially in the context of the new crown pneumonia epidemic raging around the world, the complete industrial chain and strong supply capacity of China’s biopharmaceutical industry have not only made important contributions to the global fight against the epidemic, but also become a “new driving force” for steady growth in the accelerated rise. .

In the early days of the epidemic, masks, as a necessary anti-epidemic product, were once “hard to find” in the market. Jinan City has opened up the entire industry chain of mask production in one month, and the daily output has increased from 60,000 to more than 400 times, providing a strong material guarantee for winning the battle against epidemic prevention and control.

A good “test level” is one of the “magic weapons” to effectively reduce the risk of the spread of the epidemic. In early February 2020, Jinan Yinfeng Medical Laboratory (Yinfeng Gene Technology Co., Ltd.), a subsidiary of Yinfeng Bioengineering Group Co., Ltd., quickly became the first third-party institution for nucleic acid detection of new coronavirus in Jinan. Its self-developed new crown kit has passed the EU CE certification; the self-developed first passenger car-type 5G mobile nucleic acid testing laboratory in Shandong Province can test an average of 20,000 samples per day.

Under the impact of the epidemic, a large number of enterprises have worked overtime to increase production of masks, protective clothing, ventilators and other anti-epidemic materials, which have been continuously delivered to the front lines of anti-epidemic at home and abroad. As a state-level high-tech enterprise, Shandong Broke Biological Industry Co., Ltd. urgently produced and shipped more than 5,000 biosafety equipment, air disinfection products, sterilizers and other products in just a few months.

Since the outbreak of the epidemic, my country has actively provided anti-epidemic materials to the world. There are more than 200 billion masks alone, or 30 per capita in the world. According to data released by the General Administration of Customs, in the first three quarters of 2020, China’s exports of anti-epidemic materials maintained rapid growth. Among them, the export of textiles including masks was 828.78 billion yuan, an increase of 37.5%. In addition, exports of medicinal materials and medicines, medical instruments and equipment increased by 21.8% and 48.2% respectively.

The export of high-end preparation products to European and American countries is a reflection of the comprehensive strength of my country’s biopharmaceutical enterprises. Li Yan, President of Qilu Pharmaceutical Group Co., Ltd., introduced that currently 15 personal pharmaceutical preparations of Qilu Pharmaceutical are exported to the United States, and cefepime for injection, ondansetron hydrochloride injection, and solifenacin tablets occupy the first market share in the United States; it is the first time in China Exported commercial packaged injections to Japan; 9 products were exported to the European market.

Hyaluronic acid (commonly known as “hyaluronic acid”) is widely used in orthopedics, ophthalmology, general surgery, plastic surgery and other fields of medicine and medical devices, cosmetics and health food. Zhao Yan, chairman of Bloomage Biotechnology Co., Ltd., said that relying on independent innovation, Bloomage Bio took the lead in realizing a breakthrough in the industrialization of hyaluronic acid microbial fermentation technology in China, which changed China’s production of hyaluronic acid by animal tissue extraction and mainly relying on animal tissue extraction. Due to the backwardness of imports, it has reached the forefront of the world in the field of hyaluronic acid, and its current sales cover more than 40 countries and regions.

“Innovative drugs are an important indicator to measure the innovation ability and strength of enterprises, and an important starting point to promote Chinese pharmaceutical companies to win international competition and achieve from ‘following’ to ‘running’ and ‘leading’ in the future.” Qilu Institute of Innovative Medicines Zhu Yidong, executive vice president, said.

It took 7 years for Qilu Pharma to successfully develop gefitinib tablets (Ireco), a specific drug for non-small cell lung cancer. In the more than 3 years since its launch, the price of similar imported drugs has been reduced from more than 5,000 yuan per box to more than 500 yuan; In the past 10 years, the development of bevacizumab biosimilars has been successful, and the price of the drug has also dropped significantly after the launch.

Represented by Qilu Pharmaceutical, Bloomage Bio, etc., Shandong now has a number of leading companies in the field of biomedicine. At present, Shandong has 21 national-level pharmaceutical innovation platforms, 5 drug safety evaluation research centers, and 61 drug clinical trial institutions. The scale of the pharmaceutical industry accounts for one-seventh of the country’s total.

At the same time, biopharmaceutical industry clusters have also been formed in many places in my country. In 2019, the overall scale of Beijing’s pharmaceutical and health industry exceeded 200 billion yuan, maintaining double-digit growth for four consecutive years; Jiangsu and Suzhou currently have nearly 3,000 biopharmaceutical companies with nearly 50,000 related employees. In the first three quarters of 2020, biopharmaceuticals The industry achieved revenue of about 170 billion yuan, a year-on-year increase of about 24%. It is expected that the annual revenue will exceed 200 billion yuan.

“Accelerating the research and development of innovative drugs will continue to inject new momentum into the high-quality development of my country’s biopharmaceutical industry,” said Bao Haizhong, vice president of Qilu Pharmaceutical Group. Qilu Pharmaceutical closely follows the development trend of international innovative drugs. Currently, there are more than 50 innovative drug projects under development, of which more than 10 have been approved for clinical trials. In 2020, 11 projects will apply for IND (new drug clinical trials) in China and the United States.

The “2020 China Life Science and Biotechnology Development Report” released in November 2020 pointed out that since 2010, the number of patent applications in China has maintained the second place in the world, and the number of patent authorizations in 2019 ranked first in the world. Biotechnology and new drug research and development are still the two major areas of concern for capital. China is the second largest investment and financing-intensive region in the world after the United States.

According to Tan Yong, Vice President of China Pharmaceutical Enterprise Management Association, China’s contribution to global pharmaceutical innovation has grown rapidly in recent years. A group of biopharmaceutical companies continue to make efforts in basic research and actively expand the international market. Steps towards the first echelon of global pharmaceutical innovation.


Post time: Apr-01-2022